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Abstract 
Alzheimer’s Disease (AD) is a neurodegenerative disorder that lacks effective treatment 
options. Anti-amyloid beta (A𝛽𝛽) antibodies are the leading drug candidates to treat AD, but the 
results of clinical trials have been disappointing. Introducing rational mutations into anti-A𝛽𝛽 
antibodies to increase their effectiveness is a way forward, but the path to take is unclear. In 
this study, we demonstrate the use of computational fragment-based docking and MMPBSA 
binding free energy calculations in the analysis of anti-A𝛽𝛽 antibodies for rational drug design 
efforts. Our fragment-based docking method successfully predicted the emergence of the 
common EFRH epitope, MD simulations coupled with MMPBSA binding free energy calculations 
were used to analyze scenarios described in prior studies, and we introduced rational 
mutations into PFA1 to improve its calculated binding affinity towards the pE3-A𝛽𝛽3−8 form of 
A𝛽𝛽. Two out of four proposed mutations stabilized binding. Our study demonstrates that a 
computational approach may lead to an improved drug candidate for AD in the future. 
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Introduction 
Alzheimer’s Disease (AD) is an incurable neurodegenerative disorder that leads to 
steady memory and cognitive function loss, culminating in death. At present there is no cure for 
AD, and there is a notable absence of treatment options that can reverse or effectively slow 
progression of the disease. At the level of brain tissue, AD is characterized by both the 
appearance of extracellular, fibrous plaques that are built up from the polymerization of 
amyloid beta (A𝛽𝛽) peptides1 and the appearance of intracellular neurofibrillary tangles that 
consist of hyperphosphorylated tau proteins2. Amyloid fibril deposits are hallmarks of several 
neurodegenerative diseases3, and the amyloid hypothesis states that an excessive buildup of 
A𝛽𝛽 plaques in the brain is responsible for the cognitive decline observed in AD patients. It 
suggests that clearing A𝛽𝛽 plaques from the brain would help inhibit or reverse progression of 
the disease. 
The amyloid hypothesis has been the leading theory driving therapeutic approaches for 
the treatment of AD for over two decades4. The most common therapeutic approach to AD 
treatment is immunotherapy5-7. Several active and passive anti-A𝛽𝛽 immunotherapies that 
target A𝛽𝛽 species in the brain have advanced to clinical trials, but the results thus far have been 
disappointing. The vaccine AN1792, which targeted a full-size A𝛽𝛽 1-42 peptide, advanced to 
human clinical trials in 2001 but was terminated in the phase II trial after 6% of the treated 
patients developed meningoencephalitis8.  
The result of the AN1792 trial led to the development of several passive immunization 
approaches over the next several years. Shorter regions of the A𝛽𝛽 sequence were used to 
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develop monoclonal antibodies that target different cell types in the immune system. The N-
terminal A𝛽𝛽1−15  sequence was used for A𝛽𝛽 specific B cell epitopes while A𝛽𝛽16−42  was used for 
A𝛽𝛽 specific T cell epitopes9. The choice of the epitope has a crucial effect on the ability of the 
antibody to bind to its amyloid target species. The N-terminal epitope is accessible to antibody 
binding in aggregated forms of A𝛽𝛽 while the central and C-terminal epitopes are only able to 
bind to the antibody in monomeric, or perhaps small oligomeric, forms of A𝛽𝛽 due to the central 
and C-terminal epitopes being inaccessible in mature fibril structures.  
Initially, two anti-A𝛽𝛽 monoclonal antibodies advanced to clinical trials targeting distinct 
epitopes/species of A𝛽𝛽. Bapineuzumab primarily targets insoluble amyloid plaques via the 
hydrophilic N-terminal epitope of A𝛽𝛽1−5. Initial results looked promising, but during phase II of 
the clinical trial a serious side effect appeared as 10% of patients developed vasogenic edema10. 
Solanezumab targets soluble monomeric A𝛽𝛽 peptides via the hydrophobic central A𝛽𝛽16−24  
epitope. In clinical trials, solanezumab had a much-improved safety profile as adverse side 
effects such as meningoencephalitis, microhemorrhage, and vasogenic endema were not 
obserseved11-12. On the other hand, questions about solanezumab’s efficacy in reducing neuritic 
plaque burden arose, and recently it was announced that the phase III trials for solanezumab 
had failed to show a significant benefit in slowing cognitive decline for mild-to-moderate AD 
patients13-16. 
The question of how to improve a monoclonal antibody to treat AD is not 
straightforward. Removing harmful side effects is one issue, but to complicate matters, A𝛽𝛽 
species exhibit a high degree of structural polymorphism, and several other A𝛽𝛽 species have 
emerged as potential disease-causing agents that would presumably need to be removed in an 
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effective AD treatment17.  For example, normally rare, N-terminal truncated variants of A𝛽𝛽 have 
been found in much higher concentrations in the stable, neurotoxic A𝛽𝛽 aggregates that are 
found in severe AD cases. For example, plaques can be enriched by as much as 50% with the 
pE3-A𝛽𝛽 form of A𝛽𝛽18-19, and pE3-A𝛽𝛽 has become a target in antibody development20-22.  
The existence of such polymorphic amyloid targets implies that targeting a single 
epitope associated with a single A𝛽𝛽 species might not be enough for an antibody to treat AD 
effectively. At the moment, next generation monoclonal antibodies that can bind to multiple 
A𝛽𝛽 epitopes and species are currently in clinical trials. Gantenerumab binds at nanomolar 
affinity to several A𝛽𝛽 species (with a KD of 0.6 nM for A𝛽𝛽 fibrils, 1.2 nM for A𝛽𝛽 oligomers, and 
17 nM for A𝛽𝛽  monomers), and it recognizes two epitopes within A𝛽𝛽 : the N-terminal 
EFRHDSGYEV sequence and a central region from the sequence VFFAEDVGSN23. Similarly, 
crenezumab, despite being generated by immunization with the N-terminal A𝛽𝛽1−16  epitope24-25, 
has been shown to bind to monomeric and oligomeric forms of A𝛽𝛽 via the central A𝛽𝛽 epitope7, 
25-26. Due to similarities it shares with solanezumab, the ability to bind to the central epitope of 
A𝛽𝛽 has been emphasized in studies of crenezumab27, and a co-crystal structure of crenezumab 
(more specifically, CreneFab) was recently obtained bound to an A𝛽𝛽 peptide containing the 
central epitope26. Nevertheless, crenezumab has also been shown to bind to amyloid fibril 
species25-26, which is puzzling since the central epitope is not readily accessible for binding in 
mature fibril structures. Recently, aducanumab was heralded as possibly the first “successful” 
anti-A𝛽𝛽 antibody as it was able to clear A𝛽𝛽 plaques thoroughly at the highest dosage and was 
shown to reduce cognitive decline in an early Phase III clinical trial that took place over the 
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course of a year28. Aducanumab has been reported to bind to both N-terminal and central 
epitopes of A𝛽𝛽, accounting for binding to both fibril and oligomeric forms of A𝛽𝛽29. 
In this study, we have taken a computational approach to explore how an anti-A𝛽𝛽 
antibody may bind to one or more A𝛽𝛽  epitopes in its antigen-combining site and to 
demonstrate how rational mutations aimed at modifying the antigen-combining site can be of 
use in rational drug design efforts. Using computational techniques, we explored several open 
questions from the literature including: 1) which residues in A𝛽𝛽1−42  are most important in the 
initial binding event that anchors A𝛽𝛽 to a given antibody structure?, 2) how might antibodies 
like gantenerumab, crenezumab, and aducanumab bind to both the hydrophillic N-terminal and 
hydrophobic central epitopes?, and 3) can we predict a useful mutation that improves the 
binding affinity of a polymorphic form of A𝛽𝛽 towards an anti-A𝛽𝛽 antibody? 
To address the first question, we employed an unbiased, fragment-based docking 
method to probe the antigen-combining site of various anti-A𝛽𝛽 antibodies using single amino 
acid residues. To address the second question, we ran molecular dynamics (MD) simulations 
using the available crystal structures of gantenerumab and crenezumab bound to short A𝛽𝛽 
peptides23, 26 (a crystal structure of aducanumab was not available for us to analyze at this 
time). Using Amber 1630, we carried out Molecular Mechanics Poisson Boltzmann Surface Area 
(MMPBSA) binding free energy calculations to help us explore the possibility that both N-
terminal and central A𝛽𝛽 epitopes are recognized by each antibody. For the third question, we 
built on the study of PFA1 bound to A𝛽𝛽2−7 and pE3-A𝛽𝛽3−8  that was carried out previously by 
Gardberg et al.31 Improving the binding affinity between pE3-A𝛽𝛽3−8  and PFA1 is an accessible 
test case given that the sequence, charge characteristics, and binding pose for pE3-A𝛽𝛽3−8 are 
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similar to the wildtype. A computational approach that provides a way to probe the interactions 
between an A𝛽𝛽 peptide and an anti-A𝛽𝛽 antibody, and acts as a means to test the efficacy of 
changes to the antigen-combining site, may be key to producing the most effective drug 
candidate for this disease in the long term. 
Materials and Methods  
Computational docking of amino acid residues to anti-A𝜷𝜷 antibodies 
We carried out an unbiased, fragment-based computational docking study to examine 
the initial binding characteristics of the antigen-combining site on various anti-A𝛽𝛽 antibodies. 
16 amino acids were individually docked to each antibody, comprising the full A𝛽𝛽  1-42 
monomer sequence. Each single amino acid residue was generated using the sequence 
command in xleap from Amber 1630. Three types of amino acid residue fragments were initially 
tested using our docking protocol: 1) the default amino acid residue that contained charged N- 
and C-terminal groups on the backbone, 2) a neutralized version where methyl groups were 
attached to both the N- and C-terminal groups to remove the backbone charges, and 3) a non-
physiological fragment where two hydrogens on the N-terminus and an oxygen on the C-
terminus were omitted from the structure. We compared the results of the docking for a few 
test residues using each method above to the actual binding sites observed in the PFA1 and 
PFA2 crystal structures and also to the leading ligand-free hotspots found by submitting the 
PFA1 and PFA2 apo structures to the FTMap server32-33. Of the three options, we found that 
method 3 worked the best. For method 1, the zwitterionic terminal backbone charges were 
capable of binding to antibody hot spots in place of the side chain functional groups, and while 
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method 2 neutralized the terminal backbone charges, we found that some fragments were 
unable to bind to certain hot spots due to steric issues brought about by the attached methyl 
groups. Method 3 removed both the terminal charges and the steric issue of adding a methyl 
group to the backbone. Therefore, residues were generated using method 3 for our full 
analysis. We should note that there are other possible ways to generate single amino acid 
fragments that were implemented in other computational studies, such as removing the 
backbone entirely and replacing the alpha carbon with a proton34. In order to obtain a single 
amino acid fragment that behaves more like an amino acid in the middle of a longer peptide 
sequence as opposed to a terminal amino acid, the side chain for each amino acid should be 
unaltered in the fragment while the effect of the backbone should be minimized in some way to 
prevent it from interfering or competing with the binding of the side chain. 
 After obtaining an amino acid residue, Open Babel35 was used to convert pdb files to 
pdbqt files for both the antibody and the residue, and then the residue was docked to the 
antibody using Autodock Vina/SMINA36. The residue was allowed to search the entire antibody 
surface within a 100 Å3 box that was centered on the antigen-combining site with a search 
exhaustiveness of 128. Using the default settings in Autodock Vina/SMINA, the top nine docked 
results for each residue, ranked by their most stable binding free energy values, were 
subsequently used for our analysis.  
To carry out a comparison study with a variety of anti-amyloid antibodies, this method 
was performed on the previously published crystal structures of bapineuzumab, solanezumab, 
gantenerumab, crenezumab, ponezumab, PFA1, and PFA2 in both the holo and apo forms (if 
available) of each structure (PDB IDs: 4OJF, 4XXD, 5CSZ, 5VZX, 5VZY, 3UOT, 2IPU, 2IPT, 2R0W, 
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and 2IQ9). The PDB file for each antibody complex was edited prior to docking to remove 
everything except for the residues of the isolated antibody structure.  
Molecular dynamics simulations 
To prepare the various complexes that were used in this study for MD simulations, the 
program Modeller37 was used to accomplish two purposes: 1) to model in any missing residues 
that were not present in the original PDB file, and 2) if applicable, to generate a homology 
model containing a new A𝛽𝛽 peptide that was not present in the original PDB file. Prior to using 
Modeller, the PDB file was processed to remove everything except for the A𝛽𝛽 peptide-antibody 
complex. After using Modeller, the structure was further processed using the program xleap in 
Amber 16 to add in hydrogens, water, counter ions, and disulfide bonds. A TIP3P water box was 
constructed using the solvatebox command to ensure that all atoms in the starting structure 
were no less than 12 Å from the edge of the water box. Counter ions (i.e. chloride ions) were 
added to the solvated system to give a total net charge of zero. Disulfide bonds were added 
between pairs of residues that were indicated as having disulfide bonds in the accompanying 
PDB files. For the pE3-A𝛽𝛽3−8 model (PDB ID: 3EYS), antechamber was used to parameterize the 
pyroglutamate (PCA) moiety.   
For each MD run, a 1000 step minimization was carried out with 500 steps of steepest 
descent followed by 500 steps of conjugate gradient using a non-bonded cutoff of 8.0 Å. The 
system was then heated up to a constant 300 K over a period of 50 ps under NVT conditions 
employing the Langevin thermostat. The density was equilibrated over an additional 50 ps 
under NTP conditions, and an equilibration under NVT conditions was undertaken for 
approximately 250 ns.  Finally, a 50 ns production run was carried out to bring the total 
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simulation time to 300 ns. Due to the size and high conformational flexibility of both the 
amyloid peptide and the antibody, and the extensive use of homology modeling, a long 
equilibration/production run was needed in order to achieve acceptable convergence for our 
MMPBSA binding free energy calculation (see MD method validation in Results and 
Discussion). Afterwards, the MD trajectory of our production run was visualized using UCSF 
Chimera38. In addition, to characterize alterations in binding patterns in the antigen-combining 
sites of our peptide-antibody structures, residue-to-residue percent occupancy calculations 
were carried out between select residues in the A𝛽𝛽 peptide and on the antibody surface. These 
calculations used a cutoff distance of 10 Å over 5000 frames collected at equal intervals from 
the 50 ns production run. This relatively high cutoff distance was chosen due to the high 
conformational flexibility of certain ligands in the antigen-combing site which led to a difficulty 
in identifying specific binding interactions; as a result, we do not use this measure to indicate 
such binding interactions per say, but rather, a low percent occupancy indicates a major 
decrease in the likelihood that the two residues in question can participate in such a binding 
interaction at a given site. 
MMPBSA binding free energy calculations 
5000 frames, taken at equal intervals over the 50 ns production run, were used to 
calculate the MMPBSA binding free energy39-44 for each A𝛽𝛽 peptide-antibody complex. All PBSA 
calculations were carried out using the PBSA program45-53 in the AMBER 16 package.30, 54 For 
this calculation, inp = 2 was used for the non-polar solvation model,55-56 radiopt=0 was used for 
the intrinsic atomic radii, and the ionic strength was set to 100 mM. All other settings were kept 
at the default values used in Amber 16.30, 54 Due to the rather high uncertainties in normal 
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mode analysis, the entropy contribution was neglected in our binding affinity calculations. 
Experimental binding affinities were compared to our calculated binding affinities by converting 
KD values into binding free energies using: 
∆G = RTln(KD) 
where R = 1.987 * 10-3 kcal mol-1 K -1, T = 300K, and KD is the dissociation constant in units of M. 
Results 
Computational docking of amino acid residues to anti-A𝜷𝜷 antibodies 
To address the question of which amino acids are key to the initial binding and 
anchoring of an A𝛽𝛽 peptide to an anti-amyloid antibody, we carried out an unbiased fragment-
based computational docking search using all 16 unique amino acid residues that appear in the 
A𝛽𝛽1−42  sequence. To minimize conformational effects from the polypeptide ligand, we chose to 
dock single amino acid residue fragments to the antibody surface. The goal in carrying out this 
step is to determine which single amino acid(s) are most important to the initial binding event. 
Previous studies have indicated that antibodies with extended epitopes that exhibit 
promiscuous binding have a tendency to rely on a small number of key semi-conserved anchor 
residues when binding57-58. The ability to identify key anchor residue(s) provides an important 
clue towards understanding how certain anti-A𝛽𝛽 antibodies can initially recognize both the N-
terminal and central A𝛽𝛽 epitopes despite the low sequence similarity between the two regions. 
Two criteria from the output were considered to be relevant in determining the likelihood that 
an amino acid will bind with high affinity to the antigen-combining site of the antibody: 1) 
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which residues have the strongest binding interaction at the antigen-combining site?, and 2) 
which residues find the antigen-combining site most consistently?  
TABLE 1 lists the most stable binding affinities for the top 10 ranked amino acid residues 
bound to the antigen-combining sites of ten anti-A𝛽𝛽 antibody structures. From TABLE 1, we 
observe that approximately 95% of the amino acid residues that are ranked in the top 5 appear 
in the A𝛽𝛽 1-23 region while 13% of the amino acid residues that are ranked in the top 5 appear 
in the A𝛽𝛽 24-42 region. Furthermore, 57% of the amino acid residues that are ranked in the top 
5 are found in the N-terminal DAEFRH epitope while 39% appear in the central KLVFFAED 
epitope. In particular, nine out of the ten antibodies have at least three out of four residues in 
the EFRH sequence appear in their top 5 ranking; the only exception is gantenerumab where E 
and H are tied for sixth place. These results are consistent with the noted tendency of the N-
terminal DAEFRH epitope to bind to most anti-A𝛽𝛽 antibodies59. 
In TABLE 2, we examine the number of docked amino acids found at the antigen-
combining site for each residue across the 10 different anti-A𝛽𝛽 antibodies. If we consider only 
the amino acids that were able to dock at the antigen-combining site more than half of the 
time, 79% appear in the A𝛽𝛽 1-23 region while 47% appear in the A𝛽𝛽 24-42 region. Of the 
residues that found the correct binding site more than half the time, 39% are found in the N-
terminal DAEFRH epitope while 46% appear in the central KLVFFAED epitope. In contrast to 
TABLE 1, which displayed similar results in the residue ranking for each antibody, TABLE 2 
displayed clear differences between the different highly ranked residues docked to different 
antibodies and even showed some noticeably large differences for the holo and apo forms of 
the same antibody. These latter differences are presumably due to differences in the specific 
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conformation of the antibody in the holo and apo crystal structures. It is worth pointing out 
that while charged and aromatic residues appear to dominate the top ranks in TABLE 1, the 
ability of fragments to find the active site, as observed in TABLE 2, does not correlate as 
strongly with polarity as many polar and non-polar residues tend to locate the antigen-
combining site with similar ease.  
An examination of TABLES 1 and 2 reveals an important trend in the binding pattern 
that appears to be consistent across the various antibodies that we have studied; the top two 
residues on A𝛽𝛽 1-42 that have the most stable binding free energy are either phenylalanine or 
tyrosine in all cases, and both residues are also near the top of the residues that are 
consistently docked to the antigen-combining site. Since phenylalanine and tyrosine are 
structurally identical except for a hydroxyl group, the strong binding free energy points to the 
presence of an aromatic binding pocket on the antibody that is important for binding A𝛽𝛽. The 
existence of such a binding pocket has been pointed out before as a key binding site for 
phenylalanine by several anti-A𝛽𝛽 antibody crystallographers23, 26, 59-60. In addition, the two 
prominent A𝛽𝛽 epitopes, the N-terminal DAEFRH epitope and the central KLVFFAED epitope, 
correspond to the only two locations in the A𝛽𝛽 1-42 sequence where phenylalanine appears. 
Our docking results, taken together with these observations, point towards phenylalanine as a 
leading candidate for the most important anchor residue in the initial binding of A𝛽𝛽 epitopes to 
an anti-amyloid antibody. 
MD method validation 
Although the computational docking of single amino acid residues may give us some 
insight as to which amino acids might bind first to the antigen-combining site of an anti-A𝛽𝛽 
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antibody, it does not necessarily help us understand how binding affinity emerges for an 
extended polypeptide. After the first residue in a polypeptide binds to the antigen-combining 
site, a previously accessible, high affinity binding site now becomes unavailable to other 
residues, and the binding of the first residue also restricts the search space where other 
residues can bind. In addition, our docking protocol lacks many key factors, such as the 
presence of water and the conformational motion of the full polypeptide and antibody, which 
have both been identified as being important factors in determining the selectivity of A𝛽𝛽 
peptide-antibody binding59.  
Therefore, to study the binding affinity of extended A𝛽𝛽 peptides to amyloid antibodies, 
we turned to MD simulations and MMPBSA binding free energy calculations using the Amber 16 
software suite30. First, we needed to validate our computational approach using previously 
published experimental data. To do this, we compared our MMPBSA binding free energy 
calculations to the full set of experimental binding affinities reported in the study carried out by 
Gardberg et al.  on PFA1 and PFA2 bound to various A𝛽𝛽 peptides60. FIGURE 1 shows the 
correlation of our MMPBSA calculations with the experimental data (the numerical data are 
given in TABLE 3). With a Pearson’s R value of 0.95, our MMPBSA calculations show very good 
agreement with the trend seen in the experimental binding affinity data. FIGURE S1 shows the 
convergence of our MMPBSA free energy values taken over the entire 50 ns production run. It 
is seen that our data set shows reasonable convergence over this time frame. One data point, 
for the A𝛽𝛽1−8 peptide bound to PFA1, converged very slowly and underwent a substantial 
change in its binding affinity over the 50 ns MMPBSA calculation. To verify that the MMPBSA 
result for A𝛽𝛽1−8 bound to PFA1 had converged properly, we collected 10 ns of additional MD 
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simulation data and ran a 60 ns MMPBSA calculation using the simulation data from 250 ns to 
310 ns. The 60 ns MMPBSA result showed that the 50 ns MMPBSA result had indeed already 
converged (see FIGURE S2). In general, we found that running MD simulations for a total 
simulation time of 300 ns, and using 5000 frames taken from the last 50 ns for MMPBSA 
calculations, was sufficient to produce acceptable convergence for our data.  This became the 
standard protocol that we used for any subsequent analysis. 
The importance of phenylalanine to the stable binding of A𝜷𝜷𝟐𝟐−𝟕𝟕 to PFA1 
To test the importance of phenylalanine to A𝛽𝛽 peptide-antibody binding, we studied an 
experimental scenario discussed by Gardberg et al.60. The authors carried out a binding assay 
for A𝛽𝛽2−7  and several other A𝛽𝛽2−7 sequence variants bound to PFA1. They demonstrated that 
binding affinity was lowered (from 60 nM to 3400 nM), but not completely abolished, when the 
wild type sequence, AEFRHD, was changed to the human glutamate receptor interacting 
protein 1 (or Grip1) sequence, AKFRHD. This was surprising since the charge characteristics 
completely changed from the negative glutamate residue to the positive lysine residue in the 
Grip1 peptide59. On the other hand, no binding to PFA1 was observed at all when AEFRHD was 
mutated to AEIRHD (the Position 4 or Pos4 mutant) despite the swapping of two non-polar 
hydrophobic residues59-60. We constructed homology models for the Grip1 and Pos4 mutants, 
carried out MD simulations, calculated the MMPBSA binding free energies for each, and 
compared the results to the A𝛽𝛽2−7 MMPBSA binding free energy from our method validation. 
TABLE 4 shows that the MMPBSA binding affinities qualitatively reproduce the experimental 
results from the Gardberg study quite well.  
  16 
To examine why the Pos4 (AEIRHD) mutation is much more severe than the Grip1 
(AKFRHD) mutation, we first constructed RMSD plots of the 50 ns production runs for each of 
the three relevant structures. The average RMSD values for the two mutants, Grip1 and Pos4, 
are clearly higher than the average RMSD for the A𝛽𝛽2−7 structure indicating a larger degree of 
structural change from the initial structure for the two mutants (see FIGURE S3). However, the 
RMSD plots provide no indication that the Pos4 mutant has a significantly lower binding affinity 
than the Grip1 mutant. 
Next, the MD trajectories of the three complexes were visualized and compared with 
one another. It was observed that both mutant residues were no longer able to bind to their 
original binding pockets in comparison to the wildtype A𝛽𝛽2−7  peptide. FIGURE 2 shows a 
representative frame, taken from the halfway point of the MD trajectory, to illustrate the 
situation for each structure. In the Grip1 structure, the binding pocket and the lysine residue 
have separated from each other indicating that the binding contact between the two has been 
disrupted (see FIGURE 2B). However, the rest of the residues in the A𝛽𝛽2−7  sequence remain 
bound in their proper orientations (in agreement with structural observations made by 
Gardberg at al.60), which suggests that the loss or alteration of the single glutamate binding 
interaction is the major cause of the decreased binding affinity of PFA1 for Grip1.  
The Pos4 mutation is more complicated. We note first that the isoleucine residue is 
displaced outside of the deep phenylalanine binding pocket (FIGURE 2C). Another noteworthy 
difference is that, when the isoleucine residue was pushed out of the pocket, the front half of 
the A𝛽𝛽 peptide chain rotated. The glutamate residue disassociated from its normal binding 
pocket and was found instead binding to a nearby binding pocket that normally binds to either 
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aspartate or alanine, which appear at positions 1 and 2 of the full A𝛽𝛽1−8 peptide respectively 
(FIGURE 3). Our unbiased computational docking data predicted that the Pos4 mutant would 
have a larger destabilizing effect on the binding affinity compared to the Grip1 mutant. From 
TABLE 1, phenylalanine had a top binding affinity of -5.9 kcal/mol and -6.1 kcal/mol for the holo 
and apo forms of PFA1 respectively, while glutamate had a top binding affinity of -4.5 kcal/mol 
and -4.8 kcal/mol for the holo and apo forms. However, the change in orientation of the 
binding pose in the Pos4 mutant for the full peptide clearly could not be captured by calculating 
the binding affinity for a single amino acid residue docked to the antibody surface. 
Analysis of gantenerumab and crenezumab binding to multiple A𝜷𝜷 epitopes 
Using our prior observation that phenylalanine is a very important residue for the 
binding of A𝛽𝛽 peptides to anti-amyloid antibodies, we also examined the antigen-combining 
sites of gantenerumab and crenezumab with the aim of discovering how these two antibodies 
might bind to both N-terminal and central epitopes of A𝛽𝛽 peptides. We first ran MD simulations 
and calculated MMPBSA binding free energies for both gantenerumab and crenezumab bound 
to the A𝛽𝛽 peptides observed in their crystal structures (PDB IDs: 5CSZ and 5VZY). Afterwards, 
we generated homology models containing the other prominent A𝛽𝛽 epitope that was not 
present in the original crystal structure for both gantenerumab and crenezumab.  
Four homology models that featured the new peptide were generated where:  1) each 
new A𝛽𝛽 peptide was modeled in both forward and reverse orientations across the antigen-
combining site, and 2) the location of phenylalanine residues in the A𝛽𝛽 epitopes were used for 
the initial alignment in the antigen-combining site. Calculated MMPBSA binding free energies 
are given in TABLE 5 while the convergence for our MMPBSA values is demonstrated in FIGURE 
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S4. Only the most stable homology model of the transposed A𝛽𝛽 peptide bound to each 
antibody was used for analysis; we have labeled them as “gantenerumab forward” and 
“crenezumab reverse 2” to reflect their initial alignment. The other transposed epitope 
structures were less stable and were deemed unsuitable for further analysis (data not shown).  
The N-terminal peptide, DAEFRHDSGYE, bound to gantenerumab yielded a very stable 
calculated binding free energy of -33.8 kcal/mol in comparison to the experimental value 
reported for the A𝛽𝛽 monomer bound to gantenerumab which was -10.7 kcal/mol23. FIGURE 4 
compares the initial pose of the wildtype N-terminal peptide bound to gantenerumab (FIGURE 
4A and 4B) to snapshots taken at the first, middle, and last frames of the MD production run 
(FIGURE 4C, 4D, 4E, and 4F) for our most stable model of gantenerumab bound to the central 
A𝛽𝛽 peptide.  
The source of the strong binding affinity for the N-terminal A𝛽𝛽 peptide seems apparent 
from an examination of FIGURE 4B as the antigen-combining site of gantenerumab exhibits 
several positive (blue) electrostatic contact sites on its surface that correlate with the many 
negatively charged aspartate and glutamate (red) residues that appear on the N-terminal A𝛽𝛽 
peptide. Calculated percent occupancy values for various sites can be found in TABLE S1. 
Comparing the original N-terminal A𝛽𝛽 peptide binding pose in FIGURE 4B to the binding pose of 
the transposed central A𝛽𝛽 peptide in FIGURE 4D, 4E, and 4F, we see that most of these 
electrostatic contacts have been lost when the central A𝛽𝛽 peptide is bound as it does not 
contain as many charged residues as the N-terminal peptide. However, there appear to be at 
least two potential binding interactions when the central A 𝛽𝛽  peptide is bound to 
gantenerumab: E22 to R57 and F19 to F119 (both from the VFFAED portion of the epitope) 
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appear to be close enough to interact in both structures. The percent occupancy for E3 to R57 
of 100% when the N-terminal A𝛽𝛽 peptide is bound only drops to 85.58% for E22 to R57 when 
the central A𝛽𝛽 peptide is bound, and the percent occupancy for F4 to F119 of 96.12% when the 
N-terminal A𝛽𝛽 peptide is bound actually increased to 99.92% for F19 to F119 when the central 
A𝛽𝛽 peptide is bound.  However, it is worth noting that D23 appears to be competing to some 
extent with E22 for occupancy near the R57 binding site as indicated by a noticeable 45.54% 
occupancy for D23 to R57 when the central A𝛽𝛽  peptide is bound.  In our figures this 
competition can even be seen, as E22 is clearly bound to the pocket in FIGURE 4E whereas D23 
is bound to that same site in FIGURE 4F. Outside of these two interactions, a likely interaction 
for the N-terminal peptide between R5 and Y93, with a percent occupancy of 100% (see FIGURE 
4B), is clearly lost for the central A𝛽𝛽 peptide in FIGURE 4D, 4E, and 4F as the possible 
corresponding interaction between K16 and Y93 has a 0% occupancy.  
The above observations suggest that the FAED region of the alternate A𝛽𝛽 epitope still 
may form at least a few binding contacts with the gantenerumab antigen-combining site. This is 
in qualitative agreement with experimental observations for gantenerumab, which display an 
epitope in the VFFAEDVGSN region, but do not display an epitope emerging from neighboring 
regions of the central epitope sequence that include the sequence HHQKL for instance23. The 
much less stable binding free energy of 1.8 kcal/mol that we obtained for the central A𝛽𝛽 
peptide bound to gantenerumab is also consistent with the observation that gantenerumab is 
unable to bind and alter soluble A𝛽𝛽 levels in contrast to what was observed for solanezumab, 
which preferentially recognizes the central A𝛽𝛽 epitope23, 61. 
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The central A𝛽𝛽 peptide bound to crenezumab yielded a calculated binding free energy 
of -15.2 kcal/mol. The transposed N-terminal peptide had a weaker binding free energy of -3.1 
kcal/mol. While the calculated free energy was smaller for the N-terminal peptide, the gap in 
free energy between the bound N-terminal and central A𝛽𝛽 peptides was much smaller for 
crenezumab than it was for gantenerumab. It is noteworthy to mention that the most stable 
transposed N-terminal peptide was obtained when the phenylalanine residue in the reverse N-
terminal epitope, SDHRFEAD, was aligned with F20 in the original central A𝛽𝛽  epitope, 
HHQKLVFFAEDV, prior to model building. Binding in this reverse sense in the antigen-combining 
site of an anti-A𝛽𝛽 antibody has been noted before as solanezumab binds to the central A𝛽𝛽 
peptide in this reverse sense compared to the orientation adopted by the N-terminal peptide in 
gantenerumab.59 The original binding pose of the central A𝛽𝛽 peptide bound to crenezumab is 
shown in FIGURE 5A and 5B. This may be compared to the binding pose observed for the N-
terminal peptide bound to crenezumab during the production portion of our MD simulation in 
FIGURE 5C, 5D, 5E, and 5F. Compared to the initial binding pose of the central A𝛽𝛽 peptide 
bound to crenezumab, it is seen that the binding site of crenezumab has had to distort 
considerably to bind to the N-terminal A𝛽𝛽 peptide in an alternate conformation. 
The pattern in potential binding interactions for crenezumab is qualitatively similar to 
what we saw before with gantenerumab, but in general the percent occupancy for the various 
sites that we examined are usually higher for the transposed A𝛽𝛽 peptide bound to crenezumab. 
For comparison with TABLE S1, the results of percent occupancy calculations for crenezumab 
are available in TABLE S2. The percent occupancy is 99.0% for F19 to V94 when the central A𝛽𝛽 
peptide is bound and is 100% for F4 to V94 when the N-terminal A𝛽𝛽 peptide is bound. The 
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negatively charged E3 residue also appears to be attracted to a nearby binding pocket as seen 
in FIGURE 5E and 5F; the percent occupancy for E22 to N52 is 100% when the central A𝛽𝛽 
peptide is bound and only drops to 92.28% for E3 to N52 when the N-terminal peptide is 
bound. In addition, the D23 to N53 percent occupancy of 36.94% when the central A𝛽𝛽 peptide 
is bound has actually increased to 86.3% for D1 to N53 when the N-terminal A𝛽𝛽 peptide is 
bound. Also, similar to the situation for gantenerumab, the positively charged residue in the 
alternate peptide does not stably bind to crenezumab. The percent occupancy of 100% for K16 
to D101 when the central A𝛽𝛽 peptide is bound drops to 0% for R5 to D101 when the N-terminal 
A𝛽𝛽 peptide is bound. 
In an attempt to understand why we were able to obtain a slightly stable binding free 
energy for the reverse epitope bound to crenezumab, it is noteworthy to point out the 
electrostatic similarities between the N-terminal DAEFRHD epitope and the reverse sequence of 
the central epitope KLVFFAED, which when written out in reverse becomes DEAFFVLK. When 
both sequences are compared in this way, it becomes apparent that the first four amino acids 
in the N-terminal sequence and the first four amino acids in the reverse central epitope 
sequence are very similar to each other, with DAEF and DEAF differing only by switching the 
internal positions of the alanine and glutamate residues. However, despite this similarity, the 
inability to interchange the binding of key arginine and lysine residues elsewhere in the 
sequence may help explain how crenezumab achieves its preference for the central A𝛽𝛽 peptide. 
The inability for lysine and arginine residues to cross bind for both gantenerumab and 
crenezumab is likely due to a difference in the positioning of these residues in both the 
sequence and three-dimensional space; the arginine residue appears next to the DAEF 
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sequence in the N-terminal epitope (DAEFRHDS) whereas the lysine residue appears three 
residues away from the corresponding FAED sequence in the central epitope (HHQKLVFFAEDV).  
Improving the binding affinity of PFA1 to pE3-A𝜷𝜷𝟑𝟑−𝟖𝟖 
With an eye towards the future, we wanted to see if we could use a visual inspection of 
our MD simulations to rationally plan out single amino acid mutations that improve the 
calculated MMPBSA binding free energy between an anti-A𝛽𝛽 antibody and a polymorphic A𝛽𝛽 
species. Such a computational approach has been successfully demonstrated before62, and it is 
a cost-effective way to probe for antibody mutations that could potentially improve the binding 
strength and specificity of an antibody for an additional A𝛽𝛽 target. The most promising mutants 
that are identified may then be produced and tested in a laboratory to confirm the predicted 
improvement in binding affinity at a later point.  
In order to illustrate this approach, we examined a question posed by Gardberg et al. in 
their study of pE3-A𝛽𝛽3−8 bound to the anti-protofibril antibody, PFA1. In that study, the pE3-
A𝛽𝛽3−8 amyloid peptide was shown to bind to PFA1 with less affinity (KD = 3000 nM) than the 
wild type A𝛽𝛽2−7  peptide (KD = 60 nM)31. pE3-A𝛽𝛽3−8 is still considered to be dangerous due to 
its prominent presence in Alzheimer’s plaques, and a mutant antibody that can bind to both A𝛽𝛽 
species with high affinity would be more desirable as a potential drug candidate. To probe for 
such a mutant, we first ran a preliminary MD simulation of PFA1 bound to pE3-A𝛽𝛽3−8  and 
compared it to a MD simulation of PFA1 bound to A𝛽𝛽1−8 that had been used previously in our 
method validation.  Of particular interest in the MD simulation for A𝛽𝛽1−8 was that the 
glutamate residue was found to be localized fairly well inside of its binding pocket as would be 
expected from analyzing the initial structure (see FIGURE 3). In contrast, the MD simulation for 
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pE3-A𝛽𝛽3−8 revealed that the terminal pyroglutamate (PCA3) residue was engaged in a tug-of-
war of sorts between the glutamate binding pocket and another nearby binding pocket that 
normally belongs to either alanine or aspartate.  
 Based on the MD simulations, we proposed that the difference in the observed binding 
affinity was caused by either: 1) the PCA3 residue in pE3-A𝛽𝛽3−8 lacking the full negative charge 
of the glutamate residue, weakening its attraction to the glutamate binding pocket, or 2) the 
loss of alanine in pE3-A𝛽𝛽3−8, opening up the possibility for PCA3 to be attracted away from the 
glutamate binding pocket towards the other nearby unoccupied binding pocket. On these 
grounds, we introduced two sets of single amino acid substitution mutations into the binding 
pocket of PFA1, carried out MD simulations, and calculated the MMPBSA binding free energies 
between the mutant structures and the pE3-A𝛽𝛽3−8  peptide. The first two mutants, Y59A and 
N60A on the H chain, were designed to weaken the attraction of PCA3 towards the other 
nearby binding pocket. The next two mutants, S92K and H93K on the L chain, were designed to 
strengthen the positive electrostatic character in the glutamate binding pocket.  
The MMPBSA results are given in TABLE 6, convergence plots for the calculated 
MMPBSA binding free energies are shown in FIGURE S5, and the results of percent occupancy 
calculations are available in TABLE S3. Two out of the four proposed mutants were able to 
lower the calculated binding free energy by an appreciable amount indicating that these 
mutations stabilized the bound structure. The calculated binding free energy for pE3-A𝛽𝛽3−8 
bound to the N60A PFA1 mutant was -10.2 kcal/mol, and the calculated binding free energy for 
the Y59A PFA1 mutant was -8.4 kcal/mol. These were both more favorable than the binding 
free energy of -3.9 kcal/mol calculated for pE3-A𝛽𝛽3−8 bound to the PFA1 wildtype structure. 
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The more favorable binding free energies were also comparable to values we obtained of -14.3 
kcal/mol and -10.4 kcal/mol for the original wild type A𝛽𝛽1−8 and A𝛽𝛽2−7 peptides bound to PFA1 
respectively.  
Examining the MD trajectories (FIGURE 6) revealed that our N60A mutation worked out 
more or less as we expected. The PCA3 residue was now localized closer to the two histidine 
residues near the glutamate binding pocket for the majority of the simulation time. For the 
N60A mutant, the percent occupancy for PCA3 to H27D of 97.9% and for PCA3 to H93 of 99.9% 
were large increases over the corresponding wildtype values of 19.7% and 44.0% respectively. 
In addition, the percent occupancy for PCA3 to S58, a residue near the N60A mutation site, was 
reduced from 50.9% in the wildtype to 8.6% in the N60A mutant.  
In a somewhat similar way, our Y59A mutant appeared to stabilize PCA3 by reducing its 
movement, but this time the PCA3 residue localized more towards the other nearby binding 
pocket on the central right side as indicated by an increase in percent occupancy from 50.9% to 
81.0% for PCA3 to S58. Unlike in the N60A mutant, the PCA3 residue showed only a modest 
increase in its localization towards the H27D and H93 residues with percent occupancy values 
of 25.8% and 62.4% compared to 19.7% and 44.0% in the wildtype respectively. 
The other two mutations did not improve the binding affinity of pE3-A𝛽𝛽3−8  towards the 
mutant antibody. The S92K mutant had a calculated binding free energy of 5.3 kcal/mol that 
indicated a strong destabilization of the bound structure. In the S92K mutant we note that the 
PCA3 to H27D percent occupancy decreased considerably from 19.7% to 1.0%, and also the 
PCA3 to L96 percent occupancy increased from 17.3% to 76.1%, indicating that perhaps an 
increase in percent occupancy at this particular site is disruptive to binding.  
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The H93K mutant was also destabilized as its calculated binding free energy of -2.7 
kcal/mol was a bit lower than that of the wild type pE3-A𝛽𝛽3−8 peptide bound to PFA1. It failed 
to pull PCA3 residues towards the H27D and H93 locations as we intended; the PCA3 to H27D 
percent occupancy was lowered from 19.7% in the wildtype to 0% in the H93K mutant while the 
PCA3 to K93 (the position which was previously H93) was lowered from 44.0% in the wildtype 
to 9.8% in the H93K mutant. Analysis of the MD trajectory also revealed that the pE3-A𝛽𝛽3−8 
peptide had undergone drastic changes in its binding pose for the H93K mutant. The entire 
backbone of pE3-A𝛽𝛽3−8 was flipped outwards toward the solvent, which allowed the PCA3 
residue to move into the deep central binding pocket, displacing phenylalanine. The PCA3 to 
L96 percent occupancy increased to 100% for the H93K mutant compared to 17.3% in the 
wildtype.  
Given the rather large changes in binding pose and affinity for the pE3-A𝛽𝛽3−8 peptide 
towards our PFA1 mutants, it is also reasonable to ask what changes might take place for the 
binding of the original wild type A𝛽𝛽1−8 and A𝛽𝛽2−7  peptides to our two successful mutant 
antibodies. This is an important issue if we wish to find a single antibody that is capable of 
binding with high affinity to multiple A𝛽𝛽 species. We therefore also examined MD simulations 
and calculated MMPBSA binding free energies for A𝛽𝛽1−8 and A𝛽𝛽2−7   bound to our N60A and 
Y59A mutant forms of PFA1. The binding free energies are given in TABLE 6, representative 
snapshots from the MD trajectories are shown in FIGURE 7, and the results of percent 
occupancy calculations for both wild type and mutant forms are available in TABLE S4 and S5 
for A𝛽𝛽1−8 and A𝛽𝛽2−7 respectively. 
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For both mutants, the binding affinity for A𝛽𝛽1−8  was actually improved over the 
wildtype PFA1 antibody. The calculated binding free energy for A𝛽𝛽1−8 bound to the N60A PFA1 
mutant was -18.0 kcal/mol, and the calculated binding free energy for the Y59A PFA1 mutant 
was -16.7 kcal/mol. One possible explanation for such an increase in binding affinity is that the 
percent occupancy of D1 to N27 increased to 99.9% in the N60A mutant and to 83.8% in the 
Y59A mutant compared to 79.1% in the wildtype. In contrast, both mutations slightly 
destabilized the binding of the A𝛽𝛽2−7 peptide as the calculated binding free energy for A𝛽𝛽2−7  
bound to the N60A PFA1 mutant was -8.3 kcal/mol, and the calculated binding free energy for 
the Y59A PFA1 mutant was -9.7 kcal/mol. A plausible explanation is that the mutation 
interfered with the binding of alanine, which is present in A𝛽𝛽2−7 , and also that a compensating 
D1 to N27 interaction is completely missing for this case.  
Nevertheless, if we compare the computed binding free energies of the wild type PFA1 
for A𝛽𝛽1−8, A𝛽𝛽2−7 , and pE3-A𝛽𝛽3−8  species to that of our N60A and Y59A mutants, we see that 
we have generally improved the affinity for our various A𝛽𝛽 species albeit with a modest 
sacrifice in affinity for A𝛽𝛽2−7 . In practice, a compromise between the binding of A𝛽𝛽 species for a 
given antibody can be circumvented entirely by going beyond the single antibody approach. 
Instead, a cocktail of similar antibodies can be used to target various key A𝛽𝛽 species in a 
treatment regime. In this case for instance, both wildtype and N60A mutant forms could be 
used together in a proposed treatment option to maximize effectiveness. 
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Discussion 
Anti-A𝛽𝛽 antibodies are currently the most advanced treatment option on the horizon for 
patients suffering from AD. The recent positive clinical results reported for adacanumab 
indicate the potential for these drugs to be effective at clearing plaque burden and reducing 
cognitive decline. The main issues at present are the serious autoimmune side effects 
associated with the stronger binding anti-A𝛽𝛽  antibodies and the presence of important 
polymorphic forms of A𝛽𝛽 that may not bind to an antibody drug candidate with the same high 
affinity as its primary A𝛽𝛽 target, decreasing its effectiveness. 
Although it remains a possibility to obtain new antibody drug candidates from standard 
drug screening procedures, these are expensive and time-consuming endeavors to undertake, 
and there is no way of knowing what impact the drug will have on a human population until a 
very late stage of drug development. Alternatively, there exists the possibility to rationally 
modify and improve current anti-A𝛽𝛽 antibody drugs that have already undergone clinical trials 
and whose strengths and weaknesses as a drug candidate are at least somewhat understood. 
Here, we have outlined a computational approach for studying the antigen-combining site of 
anti-A𝛽𝛽 antibodies using fragment-based docking and full molecular dynamics simulations 
accompanied by MMPBSA binding free energy calculations. Computational methods are a cost-
effective way to study the binding properties of anti-A𝛽𝛽 antibodies whose crystal structures 
have previously been made available for analysis.  
Employing a fragment-based docking method provided us with a means to dock single 
amino acid residues in an unbiased fashion to the surface of anti-A𝛽𝛽 antibodies to probe for key 
anchoring residues that are involved in the initial binding interaction. Phenylalanine emerged as 
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a dominant interaction, displaying the most stable binding free energy and very consistently 
docking into the antigen-combining sites of all ten antibodies. This observation that 
phenylalanine is a central anchor in the binding of A𝛽𝛽  peptides to anti-A𝛽𝛽 antibodies is 
corroborated by experimental observations from various crystallographers23, 26, 59-60.  
Our docking approach borrows heavily from current ideas being used in computational 
fragment-based drug design. In these methods, potential binding sites are located by probing 
the surface of a large protein receptor using small fragments of a ligand as opposed to 
attempting to dock the entire ligand32-33. A potential disadvantage to using small fragments to 
probe the receptor is a decrease in the binding selectivity for the ligand; additional binding sites 
other than the primary site of interest are often identified as potential binding sites63. On the 
other hand, conformational possibilities for a small fragment are much lower than for a larger 
ligand, and it has been shown that the leading hot spots identified using computational 
fragment-based methods correlate well with actual ligand binding sites33. In the present case, 
we were fortunate to be examining antibodies where the location of the ligand binding site was 
already known beforehand. 
In addition, MD simulations were used to study questions posed by structural biologists 
in prior work on anti-A𝛽𝛽 antibodies. In our study of PFA1, we showed that such simulations 
were capable of reproducing experimental observations as well as providing new insights into 
previously observed experimental results. We also demonstrated that MD simulations can be 
used as a tool to assist in exploratory research aimed at unravelling additional binding sites, to 
study mechanisms of binding, and to predict useful mutations to engineer into new anti-A𝛽𝛽 
antibody drug candidates. 
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The most noteworthy observation from our MD exploration of cross binding was that 
our data indicates that crenezumab may bind to both N-terminal and central A𝛽𝛽 epitopes, 
although the binding to the N-terminal region is predicted to be much weaker. This topic is of 
interest because cross binding between these two epitopes may be related to aducanumab’s 
reported ability to bind to both oligomeric and fibril A𝛽𝛽 species, and this may be a factor in its 
more optimistic outlook as a drug candidate. Additionally, it has been observed experimentally 
that crenezumab has a puzzling ability to bind to both soluble monomers, using the central 
epitope of A𝛽𝛽, and to insoluble amyloid plaques where it is believed that only the N-terminal 
epitope is readily accessible25-26. This behavior contrasts sharply with solanezumab which can 
only bind to soluble monomers using the central epitope of A𝛽𝛽 and not to fibril structures via 
the N-terminal epitope.  
To explain the cross binding to both fibril and oligomeric species observed for 
crenezumab, Ultsch et al. suggested that the A𝛽𝛽 fibril species may have defects that expose the 
central A𝛽𝛽 epitope along the fiber axis to allow crenezumab to bind to it in a few locations26. 
While this is certainly possible, the slightly stable MMPBSA binding affinity that we observed for 
binding the N-terminal peptide to crenezumab presents an alternative explanation; a weak 
binding affinity for the N-terminal epitope would give crenezumab a chance to bind to fibril 
structures to some extent. Although crenezumab’s binding affinity for the fiber form would be 
lower than for the monomer or oligomer forms that bind via the central epitope, the high 
effective concentration of potential N-terminal binding sites along a fiber axis could still 
account for the sporadic fiber binding pattern observed by Ultsch et al.26. We should note that 
other possibilities for cross binding to fibers exist than the two proposed above. Ma et al. has  
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recently pointed out that crenezumab can recognize the A𝛽𝛽 13-16 epitope which may also be 
exposed in fibers to allow the antibody to bind64. It is important to note that our analysis 
assumed that a conserved interaction between the antibody and phenylalanine was maintained 
if cross binding occurred, but this assumption may not necessarily hold if A𝛽𝛽  13-16 is 
responsible for cross binding. An interesting feature of the A𝛽𝛽 13-16 epitope is that it contains 
two side by side histidine residues, implying that a strong pH dependence for fiber binding may 
help decide experimentally between this possibility and the others mentioned above. 
Concerning our MD methodology, our analysis of gantenerumab and crenezumab is 
necessarily more limited and qualitative than our analysis of the PFA1 system. In contrast to our 
study of PFA1, we lacked a full set of experimental binding affinities that would have allowed us 
to validate our gantenerumab and crenezumab data and draw more quantitative conclusions 
for this portion of the study. In addition, while we have identified a few short sequences in the 
N-terminal and central A𝛽𝛽 epitopes that may initiate a cross binding event, other important 
aspects that can affect binding selectivity, in particular the role of entropy in conformational 
selection for the full extended polypeptide sequence59, 64-66, still needs to be quantified and 
studied in more detail. In our MD simulations, we observed a large amount of conformational 
flexibility in the both the bound A𝛽𝛽 peptides and the amyloid antigen-combining sites of our 
various model systems. Such conformational movement made it difficult to obtain converged 
free energy values for our system, which required long 300 ns MD simulations and extensive 50 
ns MMPBSA calculations to obtain acceptable convergence. We also used residue-to-residue 
percent occupancy values in our analysis, as opposed to more precise atom-to-atom 
calculations, due to the large amount of conformational flexibility that we observed. However, 
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available methods that attempt to quantify these effects for protein-ligand interactions in the 
form of entropy calculations are unsatisfactory42, and much effort is currently aimed at 
improving the accuracy and efficiency of such calculations67-70. In particular, the single 
trajectory MD/MMPBSA method that we have employed does not take into account any 
significant conformational changes that may occur between the bound and unbound states, 
and the multi-trajectory method that attempts to address this issue is known to have major 
issues with convergence69. Therefore, omitting entropy calculations is a standard practice when 
we apply the single trajectory MD/MMPBSA approach as we have done here and in past work42, 
71. Nevertheless, we do believe that a truly deep understanding of binding selectivity will need 
to take into account entropic effects in a more quantitative manner, and finding a way to 
accurately quantify the entropic effects in a highly flexible system like this would be an 
interesting avenue for a future study.   
Finally, we introduced rational mutations into the PFA1 antibody in an attempt to 
improve its binding affinity towards the pE3-A𝛽𝛽 species of A𝛽𝛽. Given the high conformational 
flexibility of both the A𝛽𝛽 peptide and the antibody itself, predicting useful mutations from static 
crystal structures would be difficult, if not impossible, to do. On the other hand, visual 
inspection of the MD simulations of the amyloid-antibody complex allowed us to rationally 
identify potential mutation hot spots on the antibody surface with relative ease. Two out of the 
four mutants were shown to stabilize the binding of pE3-A𝛽𝛽3−8  to PFA1. Other possible 
mutations may exist that can impact the binding in a similar or even better way. If a 
computational pre-screening approach such as this is carried out, it should produce a list of 
potential hot spot mutations that can then be tested in the lab to confirm the predicted 
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effectiveness. If the results from the lab correlate with the predicted computational results, an 
improved drug candidate with a greater potential to treat AD can subsequently be developed. 
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Tables  
Sequence 
A𝜷𝜷 1-23: DAEFRHDSGYEVHHQKLVFFAED 
A𝜷𝜷 24-42: VGSNKGAIIGLMVGGVVIA 
 RANK PFA1 
PFA1 
(apo) PFA2 
PFA2 
(apo) BAPI SOLA GANT 
 
 
CREN 
 
CREN 
(apo) 
 
 
PONE 
1 -5.9(F) -6.1(F) -6.4(F) -6.3(Y) -6.2(Y) -5.9(Y) -6.2(Y) -6.1(Y) -5.8(F/Y) -6.2(Y) 
2 -5.8(Y) -6.1(Y) -5.9(Y) -6.1(F) -5.9(F) -5.6(F) -5.7(F) -5.9(F) -4.9(H) -6.0(F) 
3 -5.0(R) -5.2(R) -5.1(R) -5.2(H) -5.2(H) -5.2(H) -4.8(K) -5.3(H) -4.7(R/Q) -5.3(H) 
4 -4.8(Q) -4.9(H) -5.1(H) -4.9(Q) -5.1(E) -5.0(R) -4.7(I) -5.2(R) -4.6(L) 
-4.8(D/ 
E/L) 
5 -4.6(H) 
-4.8(E/N/ 
Q) -4.8(E/Q) -4.8(E) -5.0(D) -4.7(K) -4.6(Q/R) 
-4.7(E/ 
Q) -4.5(E) 
-4.7(I/ 
K/Q) 
6 -4.5(E/N) -4.7(D) -4.6(D/L) -4.6(I) -4.9(R) -4.6(Q) 
-4.5(D/E/ 
H/L/V) -4.6(N) 
-4.4(N/ 
K/I) -4.5(V) 
7 -4.4(D/L) -4.6(I/L) -4.5(I) -4.5(L/N) -4.8(N) -4.5(E) -4.0(M) -4.5(L) -4.3(D/V) -4.2(R) 
8 -4.2(I) -4.2(V) -4.3(K) -4.4(D/K) -4.7(I) -4.4(I/L) -3.9(N) -4.4(V) -4.1(M) -4.0(M) 
9 -3.9(V) -4.1(K) -4.1(V) -4.3(R/V) -4.6(L) -4.1(N/V) -3.7(S) -4.3(D/I) -4.0(S) -3.9(S) 
10 -3.8(M) -3.9(S) -4.0(M/S) -4.2(M) -4.5(K) -3.9(D) -3.4(A) -4.2(M) -3.6(A) -3.6(A) 
 
TABLE 1. The top binding affinities for single amino acid residues bound to the antigen-
combining site of anti-A𝜷𝜷 antibodies. Binding free energies are given in units of kcal/mol while 
the corresponding amino acid is indicated by using the standard single-letter amino acid code. 
All of the structures given are based on the holo crystal structure form of the antibody except 
for those marked “(apo)” which are based on the apo crystal structure. Antibody abbreviations: 
PFA1 = protofibril antibody 1, PFA2 = protofibril antibody 2, BAPI = bapineuzumab, SOLA = 
solanezumab, GANT = gantenerumab, CREN = crenezumab, PONE = ponezumab. The A𝛽𝛽 1-42 
amino acid sequence is also provided where residues in the N-terminal epitope are highlighted 
in red, residues in the central epitope are highlighted in blue, and residues that appear in both 
epitopes are highlighted in green. 
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Tables   
Sequence 
A𝜷𝜷 1-23: DAEFRHDSGYEVHHQKLVFFAED 
A𝜷𝜷 24-42: VGSNKGAIIGLMVGGVVIA 
 
 # of Bound 
Structures PFA1 
PFA1 
(apo) PFA2 
PFA2 
(apo) BAPI SOLA GANT 
 
 
CREN 
 
CREN 
(apo) 
 
 
PONE 
9 R  F  
F/E/L/ 
I/M/V   F/Q F/K/M  
8   Y H/N/K/I Y/D/H  F R/H/K R/H/Y/L F/Y/I/L/K 
7  F H/L/M Y/D/Q/L/R N/K/Q E/F/K  E/L/I E/I  
6 F/K/L Y R/K/I F/E/M/V R I I Y/M  H/D/V/N 
5 Y R/H E  A/S Y/M K 
D/G/V/ 
N  Q/M 
4  E/Q/K/I Q A  
H/L/ 
R/Q L A Q R 
3 E/I/Q D/L/N/M  S G D/V 
A/E/ 
Q/Y  D/A/N/V A/E/S 
2 V/M V D G  G/N D/M/V S   
1 
D/H/
N A/S G/V/N/S   A/S 
H/N/ 
R/S  S/G G 
0 A/G/S G A    G    
 
TABLE 2. The number of docked structures found at the antigen-combining site of anti-A𝜷𝜷 
antibodies. The number of docked structures for each amino acid residue that were found in 
the antigen-combining site of the antibody are reported in the table above. Each amino acid is 
indicated by using the standard single-letter amino acid code. Antibody abbreviations: PFA1 = 
protofibril antibody 1, PFA2 = protofibril antibody 2, BAPI = bapineuzumab, SOLA = 
solanezumab, GANT = gantenerumab, CREN = crenezumab, PONE = ponezumab. The A𝛽𝛽 1-42 
amino acid sequence is also provided where residues in the N-terminal epitope are highlighted 
in red, residues in the central epitope are highlighted in blue, and residues that appear in both 
epitopes are highlighted in green. 
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Tables  
 
Complex Structure MMPBSA Experimental 
PFA1 (A𝛽𝛽1−8) -14.3 -10.2** 
PFA1 (A𝛽𝛽2−7) -10.9 -9.7* 
PFA1 (pE3-A𝛽𝛽3−8) -3.9 -7.6 
PFA1 (Grip1) -6.7 -7.5 
PFA1 (Ror2) -17.7 -10.5 
PFA2 (A𝛽𝛽1−8) -14.0 -10.4** 
PFA2 (A𝛽𝛽2−7) -9.5 -9.1* 
PFA2 (pE3-A𝛽𝛽3−8) -4.0 -6.7 
PFA2 (Grip1) -1.4 -6.9 
PFA2 (Ror2) -10.8 -9.7 
 
TABLE 3. Method validation of our MMPBSA calculations for A𝜷𝜷 peptides bound to PFA1 and 
PFA2. The results of MMPBSA binding free energy calculations and experimental values are 
given in units of kcal/mol. Experimental values were taken from Gardberg et al.60 and were 
converted to free energy values as described in Materials and Methods. * denotes cases where 
the experimental binding affinity values were reported as a range, and we used the average 
value of that range as the experimental binding affinity. ** denotes the experimental value 
given for A𝛽𝛽1−40  binding to both PFA1 and PFA2. The standard error of the mean was 0.1 
kcal/mol for each structure. 
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Tables  
A𝜷𝜷 Peptide MMPBSA Experiment 
A𝛽𝛽2−7 (AEFRHD) -10.9 -9.7 
Grip1 (AKFRHD) -6.7 -7.5 
Pos4 (AEIRHD) 6.8 No Binding 
 
TABLE 4. The importance of phenylalanine in the binding of A𝜷𝜷𝟐𝟐−𝟕𝟕 to PFA1. The results of 
MMPBSA binding free energy calculations, in units of kcal/mol, are given to demonstrate the 
severity of the phenylalanine Pos4 mutation (AEIRHD) in the binding of A𝛽𝛽2−7  to the antibody 
PFA1. The less severe Grip1 mutation (AKFRHD) was also included for comparison. The crystal 
structure of A𝛽𝛽2−8 bound to PFA1 (PDB ID: 2IPU) was used both for constructing the wildtype 
A𝛽𝛽2−7 peptide and for generating the homology models of the two other A𝛽𝛽 peptide mutants. 
Experimental values were taken from Gardberg et al.31, 60 and were converted to free energy 
values as described in Materials and Methods. The standard error of the mean was 0.1 
kcal/mol for each structure. 
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Tables  
Complex Structure MMPBSA Experimental 
gantenerumab (DAEFRHDSGYE) -33.8 -10.7 
gantenerumab forward (HHQKLVFFAEDV) 1.8 - 
crenezumab (EVHHQKLVFFAEDVG) -15.2 -11.7 
crenezumab reverse 2 (SDHRFEAD) -3.1 - 
 
TABLE 5. MMPBSA binding free energy results for N-terminal and central A𝜷𝜷 peptides bound 
to gantenerumab and crenezumab. The crystal structures of N-terminal A𝛽𝛽 (DAEFRHDSGYE) 
bound to gantenerumab (PDB ID: 5CSZ) and central A𝛽𝛽  (EVHHQKLVFFAEDVG) bound to 
crenezumab (PDB ID: 5VZY) were used both to calculate the MMPBSA binding free energy for 
the crystal structure-based complexes and for generating the four homology models of the 
transposed epitopes for each. Only the most stable of the four homology models of the 
transposed epitopes for each antibody were used for analysis. These are listed as 
gantenerumab forward and crenezumab reverse 2. The other structures were less stable and 
were omitted from our analysis (data not shown). The colored type for phenylalanine reveals 
the residue that was used to line up the phenylalanine residue in each homology model to the 
phenylalanine residues(s) in the original crystal structure (residues that are colored the same 
indicate the phenylalanine residue that was used for the alignment). Experimental binding free 
energies are given for the antibody structures bound to the monomer form of A𝛽𝛽23, 26. The 
results of MMPBSA binding free energy calculations are given in units of kcal/mol. The standard 
error of the mean was 0.1 kcal/mol for each structure. 
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Tables  
Complex Structure MMPBSA 
A𝛽𝛽1−8-PFA1 wildtype -14.3 
A𝛽𝛽2−7-PFA1 wildtype -10.9 
pE3-A𝛽𝛽3−8-PFA1 wildtype -3.9 
pE3-A𝛽𝛽3−8-PFA1 mutant (Y59A (H chain)) -8.4 
pE3-A𝛽𝛽3−8-PFA1 mutant (N60A (H chain)) -10.2 
pE3-A𝛽𝛽3−8-PFA1 mutant (S92K (L chain)) 5.3 
pE3-A𝛽𝛽3−8-PFA1 mutant (H93K (L chain)) -2.7 
A𝛽𝛽1−8-PFA1 mutant (N60A (H chain)) -18.0 
A𝛽𝛽2−7-PFA1 mutant (N60A (H chain)) -8.3 
A𝛽𝛽1−8-PFA1 mutant (Y59A (H chain)) -16.7 
A𝛽𝛽2−7-PFA1 mutant (Y59A (H chain)) -9.7 
 
TABLE 6. MMPBSA binding free energy results for A𝜷𝜷𝟏𝟏−𝟖𝟖, A𝜷𝜷𝟐𝟐−𝟕𝟕, and pE3-A𝜷𝜷𝟑𝟑−𝟖𝟖 bound to 
the wildtype and several mutant forms of PFA1. The crystal structure of pE3-A𝛽𝛽3−8 bound to 
PFA1 (PDB ID: 3EYS) was used both for the wildtype pE3-A𝛽𝛽3−8 -PFA1 complex and for 
generating the homology models of the four pE3-A𝛽𝛽3−8-PFA1 mutant complexes. The crystal 
structure of A𝛽𝛽2−8 (PDB ID: 2IPU) was used to generate the homology models of the A𝛽𝛽1−8 and 
A𝛽𝛽2−7 peptides bound to the N60A and Y59A mutant forms of PFA1. The results of MMPBSA 
binding free energy calculations are given in units of kcal/mol. The standard error of the mean 
was 0.1 kcal/mol for each structure. 
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FIGURE 1. Method validation for MMPBSA free energy calculations of various A𝜷𝜷 peptides 
bound to the antibodies PFA1 and PFA2. The original PFA1, PFA2, and pE3-A𝛽𝛽3−8 crystal 
structures (PDB IDs: 2IPU, 2R0W, and 3EYS) served as the basis for constructing homology 
models for all the other bound peptide structures. Our calculated MMPBSA binding free energy 
values were compared to the experimental binding affinity values reported by Gardberg et al. 
for their entire data set.60 All free energy values are given in units of kcal/mol. 
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FIGURE 2. Comparison of the binding pose for A𝜷𝜷𝟐𝟐−𝟕𝟕 peptide variants bound to PFA1.  Three 
A𝛽𝛽 peptides are shown bound to PFA1: (A) A𝛽𝛽2−7, (B) Grip1, and (C) the Pos4 mutant. All three 
images were taken at the halfway point of the production portion of the MD simulation. 
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FIGURE 3. Electrostatic contacts for A𝜷𝜷𝟏𝟏−𝟖𝟖 bound to PFA1.  A surface map of PFA1 is provided 
which shows the key electrostatic contacts made between the PFA1 antibody and charged 
residues in A𝛽𝛽1−8. The N-terminal aspartate residue (D1) on the A𝛽𝛽 peptide appears in the 
lower right corner of the figure. Negatively charged regions are depicted in red while positively 
charged regions are shown in blue. Coulombic Surface Coloring was used to depict electrostatic 
contacts where the scale ranges from -10 kcal/mol*e (pure red, negative region) to 0 
kcal/mol*e (pure white, neutral region) to 10 kcal/mol*e (pure blue, positive region). 
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FIGURE 4. Gantenerumab bound to both N-terminal and central A𝜷𝜷 peptides.  Gantenerumab 
is shown bound to the A𝛽𝛽 peptide containing the N-terminal epitope (PDB ID: 5CSZ) in the first 
frame of the MD simulation in (A) and (B). Structures (C), (D), (E), and (F) show the most stable 
central A𝛽𝛽 peptide bound to gantenerumab in the forward sequence (HHQKLVFFAEDV) across 
the gantenerumab antigen-combining site taken from the first frame (C and D), the middle 
frame (E), and the last frame (F) of the MD production run. In all structures, the N-terminus end 
of the peptide appears towards the bottom of the antigen-combining site while the C-terminus 
appears near the top. Coulombic Surface Coloring was used to depict electrostatic contacts on 
the antibody surface where the scale ranges from -10 kcal/mol*e (pure red, negative) to 0 
kcal/mol*e (pure white, neutral) to 10 kcal/mol*e (pure blue, positive). The residues on the 
peptide were colored as acidic (red), basic (blue), or neutral (white). 
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FIGURE 5. Crenezumab bound to both central and N-terminal A𝜷𝜷 peptides.  Crenezumab is 
shown bound to the A𝛽𝛽 peptide containing the central epitope (PDB ID: 5VZY) in the first frame 
of the MD simulation in (A) and (B). Structures (C), (D), (E), and (F) show the N-terminal A𝛽𝛽 
peptide bound to crenezumab in the reverse sense (SDHRFEAD) across the crenezumab 
antigen-combining site as observed in the first frame (C and D), the middle frame (E), and the 
last frame (F) of the MD production run. In structures (A) and (B), the N-terminus end of the 
peptide appears towards the bottom of the antigen-combining site while the C-terminus 
appears near the top. For (C), (D), (E), and (F), the N-terminus end appears towards the upper 
left of the antigen-combining site while the C-terminus end appears towards the lower right of 
the antigen-combining site. Coulombic Surface Coloring was used to depict electrostatic 
contacts on the antibody surface where the scale ranges from -10 kcal/mol*e (pure red, 
negative region) to 0 kcal/mol*e (pure white, neutral region) to 10 kcal/mol*e (pure blue, 
positive region). The residues on the peptide were colored as acidic (red), basic (blue), or 
neutral (white). 
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FIGURE 6. Snapshots from the MD trajectories of pE3-A𝜷𝜷𝟑𝟑−𝟖𝟖 bound to wild type and mutant 
forms of PFA1. The structures here are visualized as snapshots taken at 10 ns, 30 ns, and 50 ns 
during the production run of the MD simulation. 
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FIGURE 7. Snapshots from the MD trajectories of A𝜷𝜷𝟏𝟏−𝟖𝟖 and A𝜷𝜷𝟐𝟐−𝟕𝟕 bound to wild type and 
mutant forms of PFA1. The structures here are visualized as snapshots taken at 10 ns, 30 ns, 
and 50 ns during the production run of the MD simulation. 
